Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Lung cancer, non-small-cell, erlotinib, chemotherapy
Brief summary
The purpose of this study is to assess if the combination of erlotinib and chemotherapy (docetaxel in case of squamous cell NSCLC or pemetrexed in case of other histological types) is superior to erlotinib alone and has acceptable tolerability and safety in the 2nd line treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC).
Detailed description
Open randomized multicenter phase II study in patients in need of 2nd line treatment for advanced/metastatic NSCLC. Efficacy and safety of monotherapy with erlotinib will be compared with combination therapy of erlotinib and chemotherapy. In recent studies it was established that pemetrexed activity is more pronounced in non-squamous NSCLC in comparison to squamous cell carcinoma. Therefore in patients with non-squamous carcinoma pemetrexed will be used. As in second line treatment of NSCLC docetaxel is registered also for usage in patients with squamous cell carcinoma, docetaxel will be used in patients with squamous histology. Chemotherapy will be limited to 4 courses. Erlotinib will be continued until disease progression or unacceptable toxicity. Erlotinib as monotherapy will be administered continuously. In combination with chemotherapy, erlotinib will be given from day 2-16 of every course of 3 weeks.
Interventions
DRUGerlotinib plus docetaxel or pemetrexed
non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression. squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
DRUGerlotinib
erlotinib 150 mg/day continuously until disease progression
Sponsors
Dutch Society of Physicians for Pulmonology and Tuberculosis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed NSCLC, locally advanced and metastatic disease stage IIIB and IV. Evidence of disease progression after one or two cytotoxic treatment regimens which should have included a platinum agent. 2. Complete recovery from prior chemotherapy side effects to \< Grade 2. 3. At least one unidimensional measurable lesion meeting RECIST criteria. 4. ECOG PS 0-2. 5. Age \> 18 years. 6. Adequate organ function, including: * Adequate bone marrow reserve: ANC \> 1.5 x 109/L, platelets \> 100 x 109/L. * Hepatic: bilirubin \<1.5 x ULN, AP, ALT, AST \< 1.5 x ULN AP, ALT, and AST \<5 x ULN is acceptable if the liver has tumor involvement * Renal: calculated creatinin clearance \> 40 ml/min based on the Cockcroft-Gault formula. 7. Estimated life expectancy \>12 weeks. 8. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment. 9. Signed informed consent. 10. Patient compliance and geographical proximity that allow adequate follow up.
Exclusion criteria
1. Pregnant or lactating women. 2. Patients with medical risks because of non-malignant disease as well as those with active uncontrolled infection. 3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment. 4. Previous treatment with an EGFR-TKI, or in non-squamous histology earlier treatment with pemetrexed and in squamous earlier treatment with docetaxel. 5. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (5 day period for long-acting agents such as piroxicam). 6. Inability or unwillingness to take folic acid, vitamin B-12 supplementation or dexamethasone. 7. Concomitant treatment with any other experimental drug under investigation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From randomisation to date of first progression or date of death, assessed up to 36 months | to compare the PFS in the group receiving erlotinib alone versus the patients receiving erlotinib + single agent Progression free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events | From randomisation to 30 days after EoT all AEs are collected | to compare relevant toxicity (CTC AE vs 3.0) in the group receiving erlotinib alone versus the patients receiving erlotinib + single agent |
Countries
Netherlands
Outcome results
None listed